Mary Anne Tanay, cancer nurse at King’s College London, UK, discusses some of the findings of a thematic synthesis of available research on chemotherapy-induced peripheral neuropathy (CIPN). She talks about how CIPN is sidelined by both patients and clinicians as getting the maximum anti-tumor effects is prioritized. This is problematic as CIPN could be irreversible. She also discusses the experiences of patients who develop CIPN. The effects can often be severe, undermining patient’s ability to do everday activities such as driving or typing, impacting their social, leisure, family and work roles, potentially having significant financial implications. She highlights the lack of studies that measure patient experience of chemotherapy and peripheral neuropathy in the UK. The next steps thus are find out specifically how the UK performs in helping, supporting and informing patients with CIPN. Recorded at the 2016 Annual Meeting of the Oncology Nursing Society (ONS), held in Brighton, UK.
Get great new content delivered to your inboxSign up
By choosing to continue, you are confirming that you are a healthcare professional
Please enter your details if you would like to receive the latest oncology news and updates